SavedAdd your journal

Journals / Cukurova Medical Journal / 2020 / Cilt: 45 - Sayı: 4

Clinical, hormonal, radiological and morphological comparison of patients with clinically evident Cushing's disease and patients with silent corticotroph cell adenoma

Klinik olarak belirgin Cushing hastalığı olan hastalar ile sessiz kortikotrof hücreli adenomu olan hastaların klinik, hormonal, radyolojik ve morfolojik olarak karşılaştırılması

Gamze AKKUŞ
Baris KARAGÜN
Nuri Eralp ÇETİNALP
Arbil AÇIKALIN
Fulya ODABAŞ
Mehtap EVRAN OLGUN
Murat SERT
Suzan ZORLUDEMİR
Bekir Tamer TETİKER
Pages
1720–1732
Publication Date
2020-12-27
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

SCA can be thought of as a diverse group of pituitary adenomas.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The aim of the study was to review our clinical 7 years experiences with silent corticotroph adenoma (SCA) and Cushing disease (CD) with regard to clinical, radiological features, immunohistochemical and surgical outcomes and compare the results between two groups.
📊
Key Findings & Data:Material and Methods: We retrospectively reviewed a series of patients (n=17; SCA 10, CD 7) with corticotroph adenomas and collected biochemical, neuroradiological and pathological data of those during follow-up time.
💡
Conclusion & Impact:SCA can be thought of as a diverse group of pituitary adenomas.
🔬Design:Experimental Field Trial
📍Scope:Comprehensive Sample
⚙️Variables:pituitary adenomas · silent corticotroph adenomas · clinical comparison

Abstract

Purpose: The aim of the study was to review our clinical 7 years experiences with silent corticotroph adenoma (SCA) and Cushing disease (CD) with regard to clinical, radiological features, immunohistochemical and surgical outcomes and compare the results between two groups. Material and Methods: We retrospectively reviewed a series of patients (n=17; SCA 10, CD 7) with corticotroph adenomas and collected biochemical, neuroradiological and pathological data of those during follow-up time. Results: Mean pre-operative ACTH values of the patients with CD and SCA were 60.4±29.5, 45.5±34.6 pg/mL, respectively. Mean preoperative cortisol of the patient with CD (21.2±4.4 vs 11.5±4.0 mcg/dL) was increased than the patients with SCA measurements’. Patients with SCA had larger pituitary mass (20.4±4.5 vs 8.8±4.0 mm) than the patients with CD. And cavernous sinus invasion also was determined in all patients with SCA. Sparsely granulation staining was more common in all patients with SCA (7/10) or CD (4/7). Conclusion: SCAs are totally different from functional CD adenomas related with clinical characteristics and postoperative outcomes. SCA can be thought of as a diverse group of pituitary adenomas.

Özet

Amaç: Bu çalışmada retrospektif olarak kendi kliniğimizde takip edilen sessiz kortikotrof adenomu (SKA) olan hastalar ile belirgin kortizol sekrete eden adenomu (Cushing Hastalığı (CH)) olan hastaları klinik, radyolojik, immunohistokimyasal ve cerrahi sonuçlarına göre karşılaştırılması amaçlanmıştır. Gereç ve Yöntem: Retrospektif olarak takip edilmiş 17 hastanın 10 tanesi SKA; diğer 7 tanesi aşikar CH olan bireyleri klinik, biyokimyasal, nöroradyolojik ve patolojik verilerine göre toplayıp karşılaştırdık. Bulgular: CH olan hastalar ile SKA’sı olan hastaların preoperatif ACTH değerleri (60.4±29.5, 45.5±34.6 pg/mL) birbirine benzer olup, preoperatif kortizol değerleri (21.2±4.4 vs 11.5±4.0 mcg/dL) arasında anlamlı farklılık vardı. SKA’sı olan hastaların ortalama hipofiz adenom boyutları (20.4±4.5 mm), CH olan bireylerin ortalama adenom boyutlarından (8.8±4.0 mm) daha fazla idi. Aynı şekilde kavernöz sinüs invazyonu SKA’sı olan hastalarda daha fazla görülmekte idi. Her iki grupta immunohistokimyasal olarak seyrek granüllü boyanma paterni (SKA 7/10, CH 4/7) daha fazla görülmekte idi. Sonuç: Sessiz kortikotrof adenomlar klinik ve postoperatif sonuçları itibari ile aşikar CH olan bireylerden tamamı ile farklıdır. Bu yönü ile sessiz kortikotrof adenomları pituiter adenomların farklı bir sub-grubu gibi değerlendirmek daha doğru olacaktır.

🔖

Cite This Article

AKKUŞ, G., KARAGÜN, B., ÇETİNALP, N. E., AÇIKALIN, A., ODABAŞ, F., OLGUN, M. E., SERT, M., ZORLUDEMİR, S., TETİKER, B. T. (2020). Clinical, hormonal, radiological and morphological comparison of patients with clinically evident Cushing's disease and patients with silent corticotroph cell adenoma. Cukurova Medical Journal, Cilt: 45 - Sayı: 4, 1720–1732. https://ajindex.com/articles/101943

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Baldeweg SE, Pollock JR, Powell M, Ahlquist J. A spectrum of behaviour in silent corticotroph pituitary adenomas. Br J Neurosurg. 2005;19:38-42
  2. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP,. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2003;88:5593– 5602 3. Cooper O, Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer. 2010;1:80–92
  3. Scheithauer BW, Jaap AJ, Horvath E, Kovacs K, Lloyd RV, Meyer FB, et al. Clinically silent corticotroph tumors of the pituitary gland. Neurosurgery. 2000;47:723–29
  4. Kovacs K, Horvath E, Bayley TA, Hassaram ST, Ezrin C. Silent corticotroph cell adenoma with lysosomal accumulation and crinophagy. A distinct clinicopathologic entity. Am J Med. 1978;64:492–99
  5. Guttenberg K, Mayson S, Sawon C, Kharlip J. Prevalence of clinically silent corticotroph macroadenomas. Clin Endocrinol. 2016;85:874-80
  6. Kageyama K, Oki Y, Nigawara T. Pathophysiology and treatment of subclinical Cushing’s disease and pituitary silent corticotroph adenomas. Endocr. Journal. 2014;61:941-8
  7. Bradley KJ, Wass JA, Turner HE. Non-functioning pituitary adenomas with positive immunoreactivity for ACTH behave more aggressively than ACTH immunonegative tumours but do not recur more frequently. Clin Endocrinol (Oxf). 2003;58:59-64
  8. Nishioka H, Inoshita N, Mete O, Asa SL, Hayashi K, Takeshita A et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol. 2015;26:349-55
  9. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and Genetics of tumors of Endocrine Organs. In: PU K, LH S, editors. World Health Organization Classification of Tumours. IARC Press; City: 2004
  10. Jahangiri A, Wagner JR, Pekmezci M, Hiniker A, Chang EF, Kunwar S et al. A comprehensive longterm retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. Neurosurgery. 2013;73:8–17
  11. Tateno T, Kato M, Tani Y, Oyama K, Yamada S, Hirata Y. Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas. Endocr J. 2009;56:579–84
  12. Mete O, Lopes MB. Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol. 2017;28:228-243
  13. Nieman LK, Biller BM, Findling